IS2132B - Notkun á estrogeni til framleiðslu á lyfi til meðhöndlunar vegna tíðahvarfa - Google Patents

Notkun á estrogeni til framleiðslu á lyfi til meðhöndlunar vegna tíðahvarfa

Info

Publication number
IS2132B
IS2132B IS5468A IS5468A IS2132B IS 2132 B IS2132 B IS 2132B IS 5468 A IS5468 A IS 5468A IS 5468 A IS5468 A IS 5468A IS 2132 B IS2132 B IS 2132B
Authority
IS
Iceland
Prior art keywords
estrogen
menopause
manufacture
treatment
medicinal product
Prior art date
Application number
IS5468A
Other languages
English (en)
Icelandic (is)
Other versions
IS5468A (is
Inventor
Cummings Steven
Ellman Herman
Ettinger Bruce
Original Assignee
Univ California
Kaiser Foundation Health Plan
Permanente Medical Group Inc
Berlex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2132(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE19691937759 priority Critical patent/DE1937759A1/de
Application filed by Univ California, Kaiser Foundation Health Plan, Permanente Medical Group Inc, Berlex Lab filed Critical Univ California
Publication of IS5468A publication Critical patent/IS5468A/is
Publication of IS2132B publication Critical patent/IS2132B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
IS5468A 1967-08-12 1998-11-19 Notkun á estrogeni til framleiðslu á lyfi til meðhöndlunar vegna tíðahvarfa IS2132B (is)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19691937759 DE1937759A1 (de) 1967-08-12 1969-07-25 Benzolsulfonylsemicarbazide und Verfahren zu ihrer Herstellung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen
PCT/US1998/024677 WO1999026631A1 (en) 1997-11-21 1998-11-19 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (2)

Publication Number Publication Date
IS5468A IS5468A (is) 2000-04-26
IS2132B true IS2132B (is) 2006-08-15

Family

ID=25523181

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5468A IS2132B (is) 1967-08-12 1998-11-19 Notkun á estrogeni til framleiðslu á lyfi til meðhöndlunar vegna tíðahvarfa

Country Status (26)

Country Link
US (1) US5891868A (es)
EP (2) EP1570848B1 (es)
JP (2) JP2001523722A (es)
KR (1) KR100576568B1 (es)
CN (1) CN100398110C (es)
AT (2) ATE383862T1 (es)
AU (1) AU760108B2 (es)
BR (1) BR9814984A (es)
CA (1) CA2306881C (es)
CL (1) CL2004001852A1 (es)
CZ (1) CZ299226B6 (es)
DE (2) DE69839026T2 (es)
EA (1) EA004573B1 (es)
EE (1) EE04221B1 (es)
ES (2) ES2241188T3 (es)
HK (1) HK1082919A1 (es)
HU (1) HUP0004339A3 (es)
IL (1) IL136175A (es)
IS (1) IS2132B (es)
NO (1) NO326929B1 (es)
NZ (1) NZ504668A (es)
PL (1) PL193897B1 (es)
PT (1) PT1032398E (es)
SK (1) SK284971B6 (es)
TR (1) TR200001460T2 (es)
WO (1) WO1999026631A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
AR028196A1 (es) * 2000-01-14 2003-04-30 Sterix Ltd Composicion
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
PT1334367E (pt) * 2000-10-13 2006-10-31 Abbott Lab Metodo de determinacao da dose inicial de compostos de vitamina d
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
US20050059645A1 (en) * 2003-07-31 2005-03-17 Bodor Nicholas S. Methods for the treatment of male and female sexual dysfunction
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
RU2499583C2 (ru) * 2007-10-15 2013-11-27 Алза Корпорейшн Заместительное трансдермальное введение фентанила один раз в день
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
US20130140210A1 (en) * 2010-04-15 2013-06-06 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
US5891868A (en) 1999-04-06
ATE383862T1 (de) 2008-02-15
PL341112A1 (en) 2001-03-26
CZ299226B6 (cs) 2008-05-21
BR9814984A (pt) 2000-10-03
NO20002587L (no) 2000-07-19
ES2299912T3 (es) 2008-06-01
HUP0004339A2 (hu) 2001-05-28
EP1570848B1 (en) 2008-01-16
DE69829501D1 (de) 2005-04-28
CN1279611A (zh) 2001-01-10
TR200001460T2 (tr) 2000-11-21
PT1032398E (pt) 2005-08-31
NO326929B1 (no) 2009-03-16
KR20010032257A (ko) 2001-04-16
JP2004083599A (ja) 2004-03-18
CZ20001602A3 (cs) 2001-02-14
CN100398110C (zh) 2008-07-02
IL136175A (en) 2005-11-20
CA2306881C (en) 2008-09-02
KR100576568B1 (ko) 2006-05-08
IS5468A (is) 2000-04-26
SK7332000A3 (en) 2001-03-12
EA200000563A1 (ru) 2001-08-27
PL193897B1 (pl) 2007-03-30
EE04221B1 (et) 2004-02-16
HUP0004339A3 (en) 2001-09-28
AU760108B2 (en) 2003-05-08
ATE291430T1 (de) 2005-04-15
CA2306881A1 (en) 1999-06-03
NO20002587D0 (no) 2000-05-19
ES2241188T3 (es) 2005-10-16
CL2004001852A1 (es) 2005-06-03
DE69839026T2 (de) 2009-01-08
HK1082919A1 (en) 2006-06-23
DE69829501T2 (de) 2006-01-26
WO1999026631A1 (en) 1999-06-03
EP1032398A1 (en) 2000-09-06
DE69839026D1 (de) 2008-03-06
EE200000307A (et) 2001-10-15
IL136175A0 (en) 2001-05-20
SK284971B6 (sk) 2006-03-02
EA004573B1 (ru) 2004-06-24
AU1591499A (en) 1999-06-15
JP2001523722A (ja) 2001-11-27
EP1032398B1 (en) 2005-03-23
EP1570848A1 (en) 2005-09-07
NZ504668A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
IS5468A (is) Notkun á estrogeni til framleiðslu á lyfi til meðhöndlunar vegna tíðahvarfa
DE69720177D1 (de) Markraumnagel für die Versorgung von Frakturen der Hüfte
EP0961613A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE RESORPTION DISORDERS, INCLUDING OSTEOPOROSIS
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
HUP0104633A3 (en) Improved device for the external fixation of bones fractures, in particular ankle fractures
DE59812897D1 (de) Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
TR200200278T2 (tr) Kalsilitik bileşimler
DE69828998D1 (de) Indolderivate verwendbar zur behandlung von u.a. osteoporosis
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DE60017366D1 (de) Zugabe von behandlungsmitteln bei festphasenpolymerisationsverfahren
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis
ATE161814T1 (de) Mittel zur behandlung von bioabfällen
NO940896L (no) Fjernbar, ortopedisk brudd-stabilisator
HK1049477A1 (en) Apparatus for beauty treatment.
UA32314A (uk) Спосіб лікування некротичного панкреатиту
ITRM930670A0 (it) Cambres per fratture ossee.
UA36326A (uk) Пристрій для черезкісткового остеосинтезу поєднаних переломів таранної та п'яткової кісток